🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

McKesson (MCK) Beats On Q3 Earnings, Gains From Solid View

Published 01/31/2019, 10:11 PM
Updated 07/09/2023, 06:31 AM
US500
-
AAPL
-
MCK
-
VAR
-
ANGO
-
CNMD
-

McKesson Corporation’s (NYSE:MCK) third-quarter fiscal 2019 earnings of $3.40 per share outshined the Zacks Consensus Estimate by 6.9%. However, adjusted earnings inched down by a penny on a year-over-year basis.

Revenues came in at $56.21 billion, which outpaced the Zacks Consensus Estimate by 1.7% and improved 4.8% year over year.

Following the announcement, share prices shot up courtesy of better earnings per share guidance provided by the company. Notably, for fiscal 2019, McKesson expects adjusted earnings per share in the range of $13.45-$13.65 compared with the previous guidance of $13.20-$13.80. The midpoint of the latest guidance range of $13.55 beats the Zacks Consensus Estimate of $13.41.

In a year’s time, shares of the Zacks Rank #3 (Hold) stock has lost 25.7% compared with the industry’s 12.3% and the S&P 500 index’s 5% declines.

McKesson Corporation Price, Consensus and EPS Surprise

McKesson Corporation Price, Consensus and EPS Surprise | McKesson Corporation Quote

Segmental Analysis

Revenues at the U.S. Pharmaceutical and Specialty Solutions segment totaled $44.28 billion, up 5.5% year over year. Per management, the upside was primarily driven by market growth and acquisitions.

At the European Pharmaceutical Solutions segment, revenues amounted to $6.91 billion, down 1.1% year over year. However, the metric shot up 2% at constant currency (cc). Revenue growth was offset by reduction in owned retail pharmacies and a challenging operating environment in the United Kingdom. The segment was also impacted by unfavorable currency movements.

Revenues at the Medical-Surgical Solutions segment amounted to $2.01 billion, up 18.8% year over year.

Revenues at the Other segment were $3.01 billion in the fiscal third quarter, up 1.3% year over year and 5% at cc.

Margins

Gross profit in the reported quarter was $2.97 billion, up 9.4% on a year-over-year basis. Meanwhile, gross margin was 5.3% of net revenues, up 20 basis points (bps).

Operating income in the quarter was $683 million, down 18.1% year over year. Operating margin was 1.2%, down 40 bps.

The U.S. Pharmaceutical and Specialty Solutions segment reported adjusted operating profit of $593 million. Adjusted operating margin was 1.3% at the segment.

Adjusted operating profit at the European Pharmaceutical Solutions segment summed $71 million, while adjusted operating margin was 1 %.

The Medical-Surgical segment had adjusted operating profit of $170 million. Adjusted operating margin was 8.5% at the segment.
Adjusted operating profit was $226 million at the Other segment.

Summing Up

McKesson exited the fiscal third quarter on a solid note, with both earnings and revenues beating the consensus mark. Strong third-quarter show by core U.S. Pharmaceutical and Specialty Solutions segment buoys optimism. Also, management is optimistic about the 10-year partnership signed with Rite Aid. McKesson continues to expect incremental synergies from the MSD acquisition. McKesson Canada too saw a healthy third quarter.

These apart, the company launched an Opioid Foundation with a view to address the current U.S. opioid crisis.

On the flip side, McKesson’s European Pharmaceutical Solutions witnessed a soft third quarter due to challenges in the United Kingdom. Unfavorable currency movements too partially marred the segment’s performance. Contraction in operating income is also discouraging. Price fluctuation of generic pharmaceuticals and stiff competition in the MedTech space are added concerns.

Earnings of Other MedTech Majors at a Glance

Some better-ranked MedTech stocks that posted solid results in their respective quarters are Varian Medical Systems (NYSE:VAR) , AngioDynamics (NASDAQ:ANGO) and CONMED Corporation (NASDAQ:CNMD) .

Varian reported fiscal first-quarter adjusted EPS of $1.06, in line with the Zacks Consensus Estimate. Revenues of $741 million outpaced the consensus mark of $717.9 million. The stock has a Zacks Rank #2 (Buy).

AngioDynamics’ fiscal second-quarter adjusted EPS of 22 cents exceeded the Zacks Consensus Estimate by a penny. Revenues totaled $91.5 million, which surpassed the consensus estimate by 2.9%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

CONMED delivered fourth-quarter adjusted EPS of 73 cents, in line with the Zacks Consensus Estimate. Revenues of $242.4 million outshined the Zacks Consensus Estimate of $229.2 million. The stock carries a Zacks Rank of 2.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>



AngioDynamics, Inc. (ANGO): Free Stock Analysis Report

Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report

CONMED Corporation (CNMD): Free Stock Analysis Report

McKesson Corporation (MCK): Get Free Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.